Page 461 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C4.1. Descriptive characteristics of the randomized controlled trials and comparative cohort studies considered
relevant to KQ4 (continued)
Author, Year Study name Comparison Study Sample Inclusion criteria Population description: Quality
[Pubmed ID] /Database duration size (total) Age Comments
PSA (ng/mL)
Study design Tumor grade
Stage
Observational
studies –
clinical
outcomes
Stattin 223 NPCRSFS Surveillance Median 6849 ≤70 yr, clinically localized Mean age: surveillance, 64.7 B
2010 (AS and WW, followup = disease (T1/2), N0/x, M0/x, yr; RP, 61.2; RT, 63.4 yr
20562373 in aggregate) 8.2 yr PSA<20 ng/mL; Gleason score
vs. RP vs. RT ≤7 Mean PSA: surveillance, 7.6;
Retrospective RP, 8.2; RT, 9.3
cohort
Gleason score: surveillance, 2-
4 or WHO I/II, 95.4%; 7, 4.6%;
RP, 2-4 or WHO I/II, 82.3%; 7,
17.7%; RT, 2-4 or WHO I/II,
80.4%; 7, 19.6%

Stage: WW: T1a, 16.4%; T1b,
4.5%; T1c, 50.5%; T2, 28.6%.
RP: T1a, 1.5%; T1b, 1.4%; T1c,
53.1%; T2, 44.0%. RT: T1a,
1.2%; T1b, 2.0%; T1c, 43.7%;
T2, 53.1%.
Litwin 229 CaPSURE WW vs. RP 1.5 yr 452 Treatment within the first 6 mo Age: 65.5 yr ± 8.3 yr B
2002 vs. RT of diagnosis, had completed at
12115317 least two health-related quality PSA: 10.1 ± 11.2
of life surveys during the study
Retrospective Gleason score: 5.9 ± 1.2
cohort
Stage: T1, 30%; T2, 66%; T3/4,
4%

C-148